10 results about "Gastrin" patented technology

The present invention relates to the field of probiotics, in particular to an Akkermansia muciniphila MG784 for alleviating constipation, promoting defecation, improving intestinal barrier function and intestinal immunity, and its uses. The Akkermansia muciniphila MG784 provided by the present invention has the deposition number DSM 35549. The Akkermansia muciniphila MG784 provided by the present invention can increase the levels of motilin (MTL), gastrin (GAS), and acetylcholine in the gastrointestinal tract, promote intestinal peristalsis, improve the small intestine propulsion rate, and ameliorate defecation time and fecal output. Furthermore, Akkermansia muciniphila MG784 can also alleviate colonic mucosal inflammation, improve the thickness of the digestive tract muscular layer, modulate the structure of the intestinal microbiota, significantly increase the abundance of beneficial bacteria, and decrease the abundance of harmful bacteria.

The utility model discloses a kind of mixing equipment of gastrin 17 detection reagent, including mixing shell, the top wall of the mixing shell is provided with feed pipe, further including mixing mechanism;Mixing mechanism: it includes driving shaft, connecting rod, outer stirrer, pivot, inner stirrer and transmission assembly, the mixing equipment of this gastrin 17 detection reagent, multiple operation is driven by primary, by outer stirring component rotation around device vertical axis, to mix uniform stirring to the mixing equipment raw material of gastrin 17 detection reagent at the edge of device internal wall body, by inner stirring component rotation around device horizontal horizontal axis, to mix uniform stirring to the mixing equipment raw material of gastrin 17 detection reagent at the central part of device inside, while the mixing equipment raw material of gastrin 17 detection reagent between two groups of stirring components is mutually crossed collision mixing, effectively improve the mixing efficiency of device to the mixing equipment raw material of gastrin 17 detection reagent.

The application discloses a culture medium for constructing a gastric cancer ovary metastasis microtumor model and application. The application relates to the technical field of biotechnology, and provides a culture medium for constructing a gastric cancer ovary metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant protein EGF, bFGF, HGF, FGF-10, Wnt-3a, Noggin, R-spondin 1, Follistatin, CHIR99021, SB202190, A83-01, Primocin, N-acetyl-L-cysteine, nicotinamide, N2 additives, cholera toxin, B27, ITS-X, Y-27632, gastrin, prostaglandin E2, beta-estradiol, progesterone, Galunisertib and a basic culture medium. The culture success rate of the gastric cancer ovary metastasis microtumor model is effectively improved.

This invention discloses the application of Amomum villosum extract in the preparation of drugs for the prevention and treatment of functional dyspepsia, belonging to the field of biotechnology. The extract, when applied to the prevention and / or treatment of functional dyspepsia, can increase plasma levels of motilin (MTL) and gastrin (GAS), promote gastrointestinal motility, significantly improve gastric emptying rate in functional dyspepsia model mice, improve pathological damage to gastric tissue, restore mitochondrial function in gastric tissue, and regulate the expression of related factors in gastric tissue. Even at low doses, it can effectively increase plasma MTL and GAS levels in loperamide hydrochloride-induced functional dyspepsia model mice, improve gastric emptying rate, effectively improve pathological damage to gastric tissue in these mice, and regulate the expression of related factors in the gastric tissue. The raw materials of this invention are derived from natural products, are easy to collect, and have high safety.

Provided herein are peptide analogs of gastrin releasing peptide (GRP), corresponding pharmaceutical compositions, and methods of using such peptide analogs of GRP in the treatment of a disease or disorder, such as gastrointestinal disease or obesity.

This invention relates to compositions and methods for detecting and treating esophageal cancer, including methods for in vitro diagnosis of esophageal cancer, and to compositions and methods for preventing or treating esophageal cancer, wherein the compositions comprise antibodies that bind progastrin and the methods comprise using antibodies that bind progastrin.

This invention discloses the application of a traditional Chinese medicine composition in the preparation of drugs for the prevention and treatment of gastritis. The composition comprises the following ingredients: Astragalus membranaceus, ginseng, Atractylodes macrocephala, fermented Cordyceps militaris powder, Lycium barbarum, Hedyotis diffusa, Fagopyrum dibotrys, Bistorta officinalis, Panax notoginseng, and Caesalpinia sappan. This invention is the first to discover and confirm that this traditional Chinese medicine composition can be used to prevent or treat chronic gastritis, especially chronic atrophic gastritis. Experiments have verified that it can significantly prevent or improve the pathological state of the gastric mucosa in rats with chronic atrophic gastritis. Specifically, it can significantly increase the serum pepsinogen I / II ratio, decrease gastrin-17 levels, reverse gastric gland atrophy, and repair the morphological structure of the gastric mucosa, achieving a systematic repair of the function and structure of the CAG gastric mucosa. Furthermore, the ingredients in this traditional Chinese medicine composition are rationally combined, and no obvious toxic side effects were observed under experimental conditions, demonstrating good safety and potential for long-term use.

To provide an improved radiotherapeutic agent for treating a disease associated with abnormal expression of a gastrin-releasing peptide receptor.SOLUTION: Provided is a bombesin-derived compound of formula Ia (RX-L-Xaa1-Gln-Trp-Ala-Val-Xaa2-His-Xaa3-ψ-Xaa4-NH2). RX includes a radionuclide chelator or trifluoroborate-containing prosthetic group. L is a linker. Xaa1 is D-Phe or the like, and Xaa2 is Gly or the like. Xaa3 is Leu or the like, and Xaa4 is Pro or the like. A symbol ψ denotes reduced peptide bond between Xaa3 and Xaa4. In the case where Xaa4 is Pro or the like, ψ is CH2-N, or in the case where Xaa4 is Phe or Nle, ψ is CH2 N(R). R is H or a C1-C5 linear or branched alkyl. Use of the compound as a contrast medium or therapeutic agent is also provided.SELECTED DRAWING: None

This application provides a method for establishing and applying mouse gastric squamous cell carcinoma cell lines and gastric cancer-related fibroblast cell lines. The culture medium for culturing these cell lines comprises L-WRN cell culture supernatant, and 100×N-2 additive (0.5 vol%–1.5 vol%), 50× vitamin A-free B-27 additive (1.5 vol%–2.5 vol%), N-acetylcysteine ​​amide (1 mM–1.5 mM), nicotinamide (8 mM–12 mM), FGF-10 (80 ng / mL–120 ng / mL), EGF (40 ng / mL–60 ng / mL), A83-01 (0.8 μM–1.2 μM), Y-27632 dihydrochloride (8 μM–12 μM), Glutamax additive (0.5 vol%–1.5 vol%), and Matrigel. The culture medium provided in this application contains 5 vol%–7 vol% Hepes buffer (8 mM–12 mM) and gastrin (0.8 nM–1.2 nM). This medium can significantly improve the success rate of in vitro culture of primary cell lines. The mouse gastric squamous cell carcinoma cell lines and gastric cancer-related fibroblast cell lines obtained from this medium are genetically stable and can be used to construct ectopic or orthotopic implantation models in immune-active mice.

This invention belongs to the field of biomedicine and discloses a peptide-based therapeutic agent targeting GRPR. Specifically, it discloses a peptide-based therapeutic agent with high affinity for gastrin-releasing peptide receptor (GRPR), its pharmaceutically acceptable salt, and pharmaceutical compositions containing the same, as well as the use of the peptide-based therapeutic agent and pharmaceutical compositions in the preparation of diagnoses, preventions, and / or treatments of diseases overexpressing GRPR.